News Quantified

GILD – gilead sciences, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

GILD or VRTX: Which Is the Better Value Stock Right Now? [Yahoo! Finance]

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

3 Spectacular High-Yield Dividend Stocks to Buy in November [Yahoo! Finance]

Gilead Sciences to Present at Upcoming Investor Engagements

Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Truist Financial Co. from $83.00 to $97.00. They now have a "hold" rating on the stock.

6.8%

BEAT

-2.7%

BEAT

0.5%

BEAT

-4.6%

MISS

Form 10-Q GILEAD SCIENCES, INC. For: Sep 30

Form 4 GILEAD SCIENCES, INC. For: Nov 06 Filed by: Mercier Johanna

Form 4 GILEAD SCIENCES, INC. For: Nov 06 Filed by: Parsey Merdad

Form 144 GILEAD SCIENCES, INC. Filed by: Parsey Merdad

Form 8-K GILEAD SCIENCES, INC. For: Nov 06

Top News Gainers

3/18 Japanese flu drug appears ‘effective’ in coronavirus treatment in Chinese clinical trials [TechCrunch Blog] 9.5%

3/1 2 Stocks That Can Help You Protect Your Wealth From a Coronavirus Pandemic [The Motley Fool] 8.3%

2/25 U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool] 6.6%

3/6 Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout? [Investor's Business Daily] 6.4%

4/2 Gilead in-licenses multiple CAR antibodies from TeneoBio [Seeking Alpha] 6.2%

4/29 Gilead's remdesivir meets main goal of trial in COVID-19 patients [Reuters] 5.5%

1/31 UPDATE 2-Gilead working with China to test Ebola drug as new coronavirus treatment [Reuters] 5.0%

3/10 Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations 4.7%

3/26 Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $83.00 price target on the stock. 4.5%

4/24 European shares slide as EU stimulus fails to impress [Reuters] 3.8%

Top News Decliners

3/20 Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $90.00 price target on the stock, up previously from $70.00. -9.3%

2/27 Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Barclays PLC. They set an "underweight" rating on the stock. -9.1%

3/6 Gilead Surges To 2-Year High On Expectations For Speedy Coronavirus Drug [Investor's Business Daily] -8.4%

2/3 Gilead +12% on coronavirus treatment testing [Seeking Alpha] -7.3%

3/11 The index dropped at least 20% from its recent peak as coronavirus continues to whiplash investors [CNN] -6.6%

2/25 U.S. Stock-Index Futures Advance on Dip-Buying After Rout [Yahoo! Finance News] -6.4%

2/27 Gilead Sciences makes takeover approach to Forty Seven: Bloomberg News [Reuters] -6.3%

4/16 Gilead surges after report suggests COVID-19 patients responding to remdesivir [Reuters] -5.8%

3/24 Form DEF 14A GILEAD SCIENCES INC For: May 06 -5.6%

4/20 Dow futures fall more than 150 points as US crude prices plunge [CNBC] -5.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day